Hereditary Angioedema (HAE) is a rare genetic disorder characterised by unpredictable and potentially debilitating swelling attacks manifesting in the skin, gastrointestinal tract, and airways. In recent years, the treatment paradigm has evolved dramatically with breakthrough long-acting prophylactics and novel oral therapies enhancing both clinical outcomes and patient experience.
Mid-2025 marked a pivotal inflection point with the FDA approval of garadacimab (Andembry), pioneering factor XIIa inhibition as a novel prophylactic mechanism. This was swiftly followed by sebetralstat's July 2025 approval, establishing the first oral on-demand therapy for acute HAE attacks. These rapid market entries represent significant advancements in this historically underserved therapeutic space, creating both strategic opportunities and competitive challenges.
Leveraging physician-reported insights and real-world patient metrics from the Ipsos HAE Therapy Monitor, our comprehensive analysis report reveals emerging prescribing algorithms, changing stakeholder priorities, and precise competitive positioning opportunities. This empowers commercial teams with actionable strategic intelligence essential for optimising new product launches, defending market position, and capitalising on emerging opportunities in this dynamic disease landscape.
- Identify market trends, opportunities and decision triggers based on real-world treatment approaches
- Understand where to prioritise investment by assessing emerging unmet needs and pipeline scope
- Evaluate physician perceptions of companies in the HAE market to help enhance corporate reputation
- Learn what physicians think of existing and developing treatments, to feed into positioning and differentiating strategies
- Insights from one consistent and robust data source
- Physician-stated and real-world patient findings blended for a holistic market view
- Curated by Ipsos' dedicated rare diseases experts
Sample excerpt from report
- 30 slides per quarterly report or trended report
- Data collection timeframe: Q4 2023 and Q3 2024
- Data source: Ipsos HAE Therapy Monitor
- Respondent type: HCPs, patient record forms
- Regions shown: US
- Consistent global data, large-scale datasets